University of Oxford-founded autoimmune disease therapy developer MiroBio has launched with support from GlaxoSmithKline subsidiary SR One.

UK-based immunotherapy developer MiroBio formally launched yesterday with £27m ($33.1m) secured in a series A round featuring pharmaceutical firm GlaxoSmithKline’s SR One unit. The round was co-led by therapeutics-focused venture capital fund Samsara BioCapital and Oxford Sciences Innovation (OSI), University of Oxford’s VC fund. It included growth equity firm Advent Life Sciences. Spun out of…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.